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Abstract
Purpose—To compare the sensitivity to change and the responsiveness to intervention of the 
PROMIS Pain Interference short forms, Brief Pain Inventory (BPI), 3-item PEG scale, and SF-36 
Bodily Pain subscale in a sample of patients with persistent musculoskeletal pain of moderate 
severity.
Methods—Standardized response means, standardized effect sizes, and receiver operating curve 
(ROC) analyses were used to assess change between baseline and 3-month assessments in 250 
participants who participated in a randomized clinical effectiveness trial of collaborative telecare 
management for moderate to severe and persistent musculoskeletal pain.
Results—The BPI, PEG, and SF-36 Bodily Pain measures were more sensitive to patient-
reported global change than the PROMIS Pain Interference short forms, especially for the 
clinically improved group, for which the change detected by the PROMIS short forms was not 
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statistically significant. The BPI was more responsive to the clinical intervention than the SF-36 
Bodily Pain and PROMIS Pain Interference measures. Post-hoc analyses exploring these findings 
did not suggest that differences in content or rating scale structure (number of response options or 
anchoring language) adequately explained the observed differences in the detection of change.
Conclusions—In this clinical trial, the BPI and PEG measure were better able to detect change 
than the SF-36 Bodily Pain and PROMIS Pain Interference measures.
Introduction
Pain is the most common symptom reported in both the general population and in primary 
care.1 Musculoskeletal pain is consistently the most common, disabling, and costly of all 
pain complaints, accounting for nearly 70 million outpatient visits in the U.S. each year.1-3 
The prevalence, associated disability and cost,1, 3-5 large number of ongoing clinical trials, 
and pressure on clinicians to monitor pain as the “fifth vital sign” 6 all underscore the need 
for quality patient-reported outcome (PRO) measurement in pain.
The Patient-Reported Outcomes Measurement Information System (PROMIS) is a National 
Institutes of Health (NIH) Common Fund initiative to improve PRO measurement.7, 8 The 
PROMIS assessment system is based on a comprehensive (i.e., physical, mental, social) self-
reported health framework composed of many domains. Domains are represented as 
unidimensional hierarchies of dozens of items, called “item banks,” which are scaled using 
Item Response Theory (IRT). Item banks include many items to represent fully the range of 
impairment in a given domain. Item banks can be administered adaptively or assembled as 
static “short forms” and compared meaningfully across populations. Pain outcome domains 
in the PROMIS assessment system include pain interference, pain severity, and pain 
behavior.
A critical psychometric property of pain outcome measures, particularly important in 
clinical settings and longitudinal studies, is their ability to detect change. Clinical change 
includes both responsiveness to treatment, or the ability of a measure to accurately detect 
change when it has occurred following a treatment of known efficacy, and sensitivity to 
change, which is sometimes used synonymously with responsiveness but which does not 
require a treatment to be present.9 Studies comparing the responsiveness of legacy measures 
(i.e., older, established measures commonly developed in a classical test theory framework) 
have found comparable detection of change among pain-specific measures, including ultra-
brief (≤ 4 items) measures, but greater responsiveness and sensitivity for pain-specific 
measures versus general health status measures.10-17 Shahgholi et al.18 compared the pre-
post responsiveness of PROMIS short forms (pain behavior, pain interference and physical 
function) to that of legacy measures (Roland-Morris Disability Index, numerical rating 
scale) in a single-arm vertebroplasty intervention in a sample of 50 patients. Responsiveness 
was operationalized as a statistically significant change from baseline to 1 month in mean 
scores and similarity between measures on the categorization of patients into meaningful 
change groups (improvement, no change, decline) based on whether a participant’s change 
exceeded a criterion of 1.96 * (√2 * SEM). Results indicated that mean score differences 
between baseline and 1-month assessment points were statistically significant for all 
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PROMIS and legacy measures (p < 0.0001) and that all measures were similar on the 
percentage of participants categorized into meaningful change groups.
Stepped Care to Optimize Pain Care Effectiveness (SCOPE),19 a randomized clinical 
effectiveness trial of optimized analgesic therapy delivered by a collaborative telecare 
intervention in primary care, incorporated longitudinal assessment of pain severity, 
interference, and pain-related disability. We sought to assess pain interference measures for 
sensitivity to change (with respect to a retrospective global anchor item) in the combined 
control and intervention samples, and responsiveness to treatment (i.e., attributable to a 
multicomponent stepped care intervention provided in the SCOPE trial) compared to a 
control group. To our knowledge, this is the first study to compare responsiveness of 
PROMIS and legacy measures in the context of a randomized controlled trial.
Methods
Measures
PROMIS Pain Interference Short Forms—PROMIS Pain Interference short forms are 
composed of items from the unidimensional PROMIS Pain Interference item bank, one of 
eight PROMIS item banks that were designed to measure physical functioning as a 
component of overall self-reported health and validated in large clinical and community 
samples. The PROMIS Pain Interference items are scaled from 1-5, with response options 
“Not at all,” “A little bit,” “Somewhat,” “Quite a bit,” and “Very much,” respectively. We 
assessed responsiveness of the 4-item pain interference short form included in the 
PROMIS-29 Profile instrument, the 8-item pain interference short form included on the 
PROMIS-57 Profile instrument, and the stand-alone 6-item PROMIS Short Form v1.0 – 
Pain Interference 6b. Short forms rather than adaptively administered item banks were 
chosen as these were more easily adopted into the study data collection process and may be 
more feasibly adopted in a diversity of clinical settings. Raw scores were converted to IRT-
derived T-scores using the scoring manuals available at http://assessmentcenter.net
Brief Pain Inventory—The Brief Pain Inventory (BPI) is an 11-item pain measure 
validated initially in cancer populations 20 and later in other clinical populations.13, 21 The 
BPI measures two domains of pain: a 4-item severity dimension and 7-item interference 
dimension. Both the BPI severity and interference items are scaled from 0-10, with response 
options at scale point 0 and 10, respectively, of “No pain” and “Pain as bad as you can 
imagine” for the severity items and of “Does not interfere” and “Interferes completely” for 
the interference items. We assessed responsiveness of the 4-item severity and the 7-item 
interference subscales separately and also together as an 11-item total.
PEG Scale: The ultra-brief 3-item PEG measure was derived from the BPI and validated in 
ambulatory care settings.22 The PEG includes 1 severity item (average pain) and 2 
interference items (enjoyment of life and general activity) and uses the same scales and 
scoring (i.e., mean of item scores) as the BPI.
SF-36 Bodily Pain—The 2-item Bodily Pain subscale of the Medical Outcomes Study 
SF-36 questionnaire has been validated in a wide range of populations.23, 24 One item 
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assesses pain interference on a 1-5 scale, with response options “Not at all,” “A little bit,” 
“Moderately,” “Quite a bit,” and “Extremely.” The other item assesses pain severity on a 1-6 
scale, with response options “None,” “Very mild,” “Mild,” “Moderate,” “Severe,” and 
“Very severe.” We assessed the responsiveness of the two items together, as a scale. 
Responses are transformed into a 0 to 100 score.
Reference Standard – Patient-reported global change: A single item assessing patient-
reported global change 25 from baseline to the 3-month assessment was used as the reference 
standard for responsiveness. The item asked, “How would you describe your pain now, 
compared to how you were when you started in our study?” The item was scaled from 1-7, 
with response options “Much better,” “Moderately better,” “A little better,” “No change,” 
“A little worse,” “Moderately worse,” and “Much worse,” respectively.
Details of the SCOPE trial design and study measures have been published.19 Briefly, the 
SCOPE trial enrolled veterans with moderate to severe and persistent musculoskeletal pain 
from one of five primary care clinics at the VA Medical Center in Indianapolis. 
Musculoskeletal pain was defined as regional (joints, limbs, back, neck) or more generalized 
(fibromyalgia or chronic widespread pain). Nonmusculoskeletal single-site pain syndromes 
(headache, facial pain, chest pain, abdominal pain) and inflammatory types of arthritis that 
would be treated with disease-modifying drugs (e.g., rheumatoid arthritis) were excluded. 
Moderate to severe pain was defined as a Brief Pain Inventory item score ≥5 for either the 
patient’s average or worst pain in the past week. Persistent was defined as pain that 
continued for ≥3 months despite trying at least one analgesic medication. The study 
excluded those who did not speak English, had moderately severe cognitive impairment or 
psychoses, had a pending pain-related VA or Social Security disability claim, were actively 
suicidal, had current illicit drug use, or had an anticipated life expectancy of less than 12 
months. The SCOPE study protocol was approved by the Indiana University Institutional 
Review Board and the VA Research Review Committee.
A total of 250 participants were enrolled in the SCOPE study. The study patients had a mean 
age of 55.1 years (range, 28 to 65); 83% were men; 77% were white, 19% black, and 4% 
other race. The mean baseline BPI total pain score was 5.2 (1.8), representing a moderate 
level of pain. The duration of pain was 1 year or longer in 98% of participants. The results 
reported here represent the data from the 244 patients who completed both baseline and 3-
month assessments.
Analyses
Sensitivity to change: Standardized Response Means and Area Under the 
Curve—Standardized response means (SRM) are effect size measures of within-group 
change that are computed by standardizing the difference between mean scores within a 
group at two time points.26 SRMs compare the average change to the variability in change 
and thus show the size of the change relative to a unit of 1.0 SD:
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SRMs were used as the effect size to measure the magnitude of the sensitivity to change 
between baseline and 3 months on each scale in each of three global change reference 
groups: those who were worse (global change item categories 5-7), those who were the same 
(category 4), and those who were better (categories 1-3).
In addition, the ability of the measures to detect any improvement (global change < 4) and 
moderate improvement (global change < 3) was investigated using receiver operating 
characteristic (ROC) analyses. Area under the curve (AUC) values can range from 0.5 (the 
same as chance) to 1.0 (perfect discrimination) and are interpreted as the probability of a 
measure correctly discriminating between patients who have improved and those who have 
not.
Responsiveness to intervention: Standardized Effect Size—Standardized effect 
sizes (SES) are effect size measures of between-group difference of change that are 
computed by standardizing the difference between change-score means of two independent 
groups:26
SESs were used as the effect size to measure the magnitude of the responsiveness of the 
scales to the SCOPE collaborative telecare intervention. Primary results of the SCOPE trial 
showed the intervention was effective in reducing persistent musculoskeletal pain and pain-
related functional limitations.19 Cohen’s rule of thumb interpretative guidelines for two-
group standardized mean difference effect sizes (i.e., 0.2 is small, 0.5 is medium, and 0.8 is 
large)27 were used to assess the magnitude of the effects.
Results
Sensitivity to change: Standardized Response Means and Area Under the Curve
Table 1 shows the measure-level sensitivity to change for pain measures in the SCOPE 
study, including baseline and 3-month scores for each measure and each (i.e., Worse, Same, 
Better) group, the change in scores between baseline and 3-months, the statistical 
significance of the change between reference (i.e. Same) and other (Worse, Better) groups, 
and corresponding SRM values. The independent-group t-test comparison between groups 
on the change scores from baseline to 3-months revealed that the Worse group showed 
statistically significant greater change on all measures relative to the Same group change 
scores. These t-tests showed that the Better group demonstrated statistically significant 
greater change than the Same group on all BPI variants (Severity, Interference, Total), the 
PEG scale, the SF-36 Bodily Pain subscale, and the PROMIS Pain Interference Short Form 
6b, but not on the PROMIS Profile short forms (Profile-29, Profile-57).
Across all measures, effect size estimates of change (Table 1) for the Same (−0.38 to 0.38) 
and Worse (−0.47 to 0.17) groups were small. In the Better group, effect size estimates for 
all BPI variants (0.71 to 0.94), PEG (0.86), and SF-36 Bodily Pain (−0.71; reverse-scaled) 
were medium to large, whereas effect size estimates for all PROMIS variants were small to 
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medium (0.34 to 0.51). The overlapping confidence intervals indicate that few differences 
are statistically significant.
Table 2 shows the area under the ROC curve (AUC) for each measure. Consistent with the 
SRM analysis, all BPI variants and the PEG showed greater responsiveness than all 
PROMIS variants and the SF-36 Bodily Pain subscale. The responsiveness of BPI variants 
and the PEG to any global improvement (0.677 to 0.727) was similar to their responsiveness 
to moderate improvement (0.694 to 0.743). The responsiveness to any improvement (0.679) 
was also similar to that of moderate improvement (0.644) for the SF-36 Bodily Pain 
subscale, as were the ranges of PROMIS short form AUC values to any (0.562-0.612) and 
moderate improvement (0.597-0.661).
Responsiveness to intervention: Standardized Effect Sizes
Table 3 shows measure-level responsiveness to intervention for treatment and control 
groups, including group change and corresponding standardized effect size estimates for all 
pain measures. All BPI variants (0.37 to 0.42) and the PEG (0.37) were more responsive to 
the SCOPE intervention than PROMIS variants (0.17 to 0.28) and the SF-36 Bodily Pain 
subscale (−0.25; reverse-scaled).
Post-hoc analyses of item-level responsiveness and BPI rating scales
Post-hoc analyses of sensitivity to change and responsiveness to intervention at the 
individual item level were undertaken to investigate whether the differences in item content 
could help explain the measure-level findings. Item-level results were generally consistent 
with the measure-level results (item results available from authors). Across all items, effect 
size estimates of sensitivity to change for the Same (−0.36 to 0.41) and Worse (−0.40 to 
0.19) groups ranged between small and medium. In the group that reported overall 
improvement in pain at 3 months, effect size estimates for all BPI items (0.32 to 0.92) and 
SF-36 Bodily Pain (−0.58 to −0.66; reverse-scaled) generally ranged from medium to large, 
whereas effect size estimates for all PROMIS items ranged from small to medium (0.16 to 
0.40).
Table 4 displays BPI, PROMIS, and SF pain interference short form item content, ordered 
from most to least similar, to facilitate comparison of item-level sensitivity to change. 
Comparison of SRM values shows that BPI and SF items were each more sensitive to 
change than any PROMIS item, regardless of item content. Unique BPI items (i.e., mood, 
walking ability, sleep) were no more sensitive to change than BPI items with other content. 
Similarly, the unique PROMIS item (i.e., ability to concentrate) was not less sensitive to 
change than PROMIS items with other content. Conceptually similar BPI and SF items were 
more responsive than corresponding PROMIS items.
Table 5 shows item-level responsiveness to intervention for treatment and control groups, 
including group change and corresponding standardized effect size estimates for all items. 
The intervention effect size ranged from small to medium for all items. However, BPI items 
(0.11 to 0.56) were generally more responsive to the SCOPE intervention than PROMIS 
(−0.05 to 0.27) and the SF-36 Bodily Pain items (−0.17 to −0.25; reverse-scaled).
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Discussion
Using longitudinal data collected in the SCOPE effectiveness trial, we found that PROMIS 
Pain Interference short forms were less sensitive to change (with respect to a global 
retrospective anchor) and less responsive to treatment than BPI severity, interference, total, 
and PEG scales, especially in the group who demonstrated global improvement. The 
differences in sensitivity to change and responsiveness to treatment held at the item level, as 
well, and did not appear to result from content differences between the short forms. The 
overlapping confidence intervals indicated that few differences were statistically significant, 
which given the magnitude of the differences in effect size, is likely a function of the size of 
the study sample. The performance of PROMIS Pain Interference short forms relative to the 
SF-36 Bodily Pain subscale depended on the outcome: the PROMIS short forms were less 
sensitive to change than the SF-36 Bodily Pain subscale (i..e, SRM analyses using global 
change categories) but similarly responsive to the SCOPE intervention in both measure- and 
item-level analyses (i.e., SES analyses using between-group treatment effects). Decreased 
responsiveness and less sensitivity to change renders measures less capable of registering 
improvement or decline.
The poorer sensitivity to change of PROMIS pain interference measures in the study may be 
attributable to the duration of the study interview and to the order of presentation of 
measures. The BPI was administered near the beginning of the 30-45 minute interview, 
whereas the PROMIS and SF-36 Bodily Pain items were administered near the end of the 
interview. Respondent fatigue arising from the length of interview overall or the large 
number of pain items in particular could have led to less discrimination in participants’ 
responses to PROMIS pain items. However, subjects were informed at the beginning of the 
interview that some questions may seem redundant but was done intentionally for research 
purposes. Moreover, the respondent burden was similar to that in several previous trials 
showing comparable responsiveness of pain measures.13, 14 Additionally, the respondent 
burden in the current study was certainly not greater than that in the item bank validation 
studies undertaken by the PROMIS group. Perhaps most importantly, the SF-36 Bodily Pain 
subscale items were adjacent to the PROMIS items near the end of the interview but showed 
greater sensitivity to change than PROMIS items. It is also important to note that the 
structure of the interview, in which the global change item fell immediately after PROMIS 
and SF-36 Bodily Pain items, would seem to promote concordance and, thus, greater 
sensitivity to change rather than less. Taken together, the interview duration and structure do 
not appear to be viable explanations for the differences in sensitivity to change found in this 
study. Although the pain measures in SCOPE were not self-administered bur rather 
completed by interviewer-administration, the available evidence suggests that mode of 
administration has minimal, if any, effect on the psychometric properties of PROMIS 
measures.28
Another potential explanation for differences in sensitivity to change is the possibility of an 
artifactual relationship based upon similarities between the response structures of the study 
measures and the reference standard for change. However, the opposite was true: there was a 
greater degree of association between scores of the global change (7 verbally anchored 
response options) and the BPI (11 numeric response options anchored only at the tails) 
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despite the similarities between the response structures of the global change, PROMIS (5 
verbally anchored response options) and SF-36 Bodily Pain (5 or 6 verbally anchored 
response options) measures. Thus, differences in response structures cannot explain 
differences found in the sensitivity of the measures to change.
The greater responsiveness to treatment of BPI may have resulted from the use of two BPI 
items (worst pain and average pain) for baseline eligibility and use of the PEG, a 3-item 
scale derived from the BPI, in the automated symptom monitoring (ASM) in the 
intervention arm. More responsiveness could arguably be expected in the questionnaire that 
was used to constrain baseline eligibility. In addition, treatment may have been adjusted to 
optimize the PEG score and the BPI by virtue of the shared content between the measures, 
thus optimizing its change relative to other pain scales. Also, it is possible that the 
intervention group who received automated symptom monitoring as a part of treatment were 
“trained” on the 0-10 scale. However, in previous trials where automated symptom 
monitoring was not done (i.e., SCAMP trial) or was done with a 5-item BPI (i.e., INCPAD 
trial), the differences in BPI and non-BPI pain scale responsiveness were subtler than those 
found in the present study.29, 30 Nevertheless, we acknowledge that this study was not 
designed to compare these scales head-to-head, with random ordering; thus the issues 
considered above render the results somewhat less robust to alternative interpretations.
The poorer responsiveness to treatment of the PROMIS pain interference short forms 
relative to the BPI, PEG, and SF measures contrast with findings reported by Shahgholi et 
al. Some degree of difference between studies might be expected between the present study 
and that by Shahgholi et al. as a result of differences in design (randomized, controlled trial 
vs. consecutive cohort), differences in the type and chronicity of pain (i.e., chronic and 
commonly multisite musculoskeletal pain vs. vertebral fracture), differences in the 
indicators of change (patient global impression vs. statistical thresholds), and difference in 
sample size (244 vs. 50). However, it seems more likely that these elements could explain 
between-study rather than within-study differences.
The data in this study strongly suggest that the unique item content of the BPI (i.e., mood, 
sleep and walking) does not explain the differences in sensitivity to change and 
responsiveness to treatment between PROMIS short forms and BPI interference items. All 
BPI items, not just the unique items (i.e., mood, sleep and walking) had larger SRM values 
than PROMIS short form items for the clinically improved group. Conceptual differences 
may be a significant driver of the differences in responsiveness. It may be the case that 
instruments measuring symptom severity are more responsive to treatment effects than 
instruments measuring the impact/interference of the symptom on day-to-day activities as 
the latter are more distal to what is actually changing.
PROMIS pain interference measures were validated in a general population sample 
augmented with a sample of participants with chronic pain to ensure reporting higher levels 
of pain. Still, it may be possible that these PROMIS short form items exhibit less 
heterogeneity of responsiveness in clinical populations. Short forms composed of items that 
maximize precision of measurement across the full continuum of pain could potentially 
contribute to a lack of heterogeneity if change occurs in a restricted range of the continuum. 
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Direct item-level comparison of PROMIS, BPI and SF-36 Bodily Pain content suggests the 
differences in responsiveness to intervention and sensitivity to change are difficult to 
attribute to differences in the conceptual targets of items. Special factors about clinical 
samples might also make a difference in responsiveness: receiving a pain intervention if in a 
trial; higher rates of important pain comorbidities such depression; pain type, bodily 
location, or chronicity of pain; and clinical population (e.g., primary care, cancer, specialty 
pain clinics, etc.). It is important to note that the effect sizes reported here are based on small 
sample sizes and are dependent on the variances of the measures in this particular sample. 
Interpretation and conclusions about the generalizability of the findings should be made 
cautiously.
As the detection of sensitivity to change is important for cohort studies, and the detection of 
responsiveness to treatment is essential for clinical trials, future studies of PROMIS pain 
interference scales are sorely needed prior to adoption of these measures as primary research 
outcomes. Future studies should consider counter-balancing the order of administration of 
measures and including both static and adaptive item administration. In the future, 
alternatives to the effect size estimates reported here, such as an SEM-based approach or the 
assessment of change at the individual level in the context of an IRT model, could be 
considered.
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Table 1
Measure-level sensitivity to change for pain measures in SCOPE trial (overall n = 244: worse n = 51; 
same n = 96; better n = 97)
Pain measure
 Global category
Baseline
score (SD)
3 month score
(SD)
Change score
(SD)*
P-
value†
SRM‡ (95% CI)
BPI Severity
 Worse 5.10 (1.42) 5.76 (1.50) −0.66 (1.40) <0.001 −0.47 (−0.75, −0.19)
 Same 5.19 (1.77) 5.02 (1.89) 0.17 (1.35) -- 0.13 (−0.08, 0.33)
 Better 5.12 (1.78) 3.89 (2.09) 1.23 (1.72) <0.001 0.71 (0.51, 0.92)
BPI Interference
 Worse 5.45 (2.21) 5.40 (2.25) 0.05 (1.82) 0.044 0.03 (−0.25, 0.31)
 Same 5.38 (2.26) 4.73 (2.29) 0.70 (1.86) -- 0.38 (0.18, 0.58)
 Better 5.18 (2.18) 3.48 (2.26) 1.70 (1.81) <0.001 0.94 (0.74, 1.14)
BPI Total
 Worse 5.28 (1.59) 5.58 (1.63) −0.30 (1.36) 0.002 −0.22 (−0.50, 0.06)
 Same 5.28 (1.86) 4.85 (1.99) 0.44 (1.41) -- 0.31 (0.11, 0.51)
 Better 5.15 (1.82) 3.69 (2.02) 1.47 (1.57) <0.001 0.93 (0.73, 1.14)
PEG
 Worse 5.33 (1.96) 5.56 (2.00) −0.23 (1.68) 0.028 −0.14 (−0.42, 0.15)
 Same 5.41 (2.13) 4.92 (2.20) 0.48 (1.92) -- 0.25 (0.05, 0.45)
 Better 5.36 (2.12) 3.70 (2.28) 1.66 (1.93) <0.001 0.86 (0.66, 1.06)
SF-36 Bodily Pain
 Worse 33.78 (15.89) 31.33 (14.35) 2.45 (14.83) 0.002 0.17 (−0.12, 0.45)
 Same 33.78 (16.01) 38.95 (16.52) −5.18 (13.76) -- −0.38 (−0.58, −0.17)
 Better 35.80 (17.23) 47.65 (20.12) −11.85 (16.60) 0.003 −0.71 (−0.92 −0.51)
PROMIS®-29 Profile
Pain Interference Short
Form
 Worse 60.72 (7.33) 61.35 (7.05) −0.63 (5.45) 0.020 −0.11 (−0.40, 0.17)
 Same 60.47 (7.24) 58.80 (7.25) 1.67 (5.71) -- 0.29 (0.09, 0.49)
 Better 59.00 (6.99) 57.05 (7.44) 1.95 (5.87) 0.730 0.33 (0.13, 0.53)
PROMIS®-57 Profile
Pain Interference Short
Form
 Worse 60.41 (7.56) 61.23 (7.37) −0.82 (5.22) 0.010 −0.16 (−0.44, 0.13)
 Same 60.26 (7.75) 58.64 (7.55) 1.63 (5.50) -- 0.30 (0.09, 0.50)
 Better 59.00 (7.04) 56.79 (7.69) 2.20 (5.92) 0.483 0.37 (0.17, 0.57)
PROMIS® Pain
Interference Short Form
6b
 Worse 60.70 (7.79) 60.83 (6.59) −0.14 (5.55) 0.010 −0.02 (−0.31, 0.26)
 Same 60.01 (7.39) 58.67 (7.21) 1.34 (4.95) -- 0.27 (0.07, 0.47)
 Better 59.08 (6.73) 56.08 (7.60) 3.01 (5.92) 0.036 0.51 (0.31, 0.71)
Med Care. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kean et al. Page 12
*
change calculated as (baseline - 3 month).
†p-value derived from 2-sided independent t-test comparing change scores between reference (i.e. “Same) and other groups
‡Standardized response mean, an effect size of the magnitude of within group change, calculated as (baseline – 3 month) / SD change score.
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Table 2
Area under the receiver operating characteristic curve (AUC) for pain measures (n=244) 
in SCOPE trial
Accuracy for detecting any
improvement
Accuracy for detecting
moderate improvement
AUC SE AUC SE
BPI Severity .727 .033 .737 .041
BPI Interference .677 .035 .694 .042
BPI Total .727 .033 .743 .041
PEG .707 .034 .716 .043
SF-36 Bodily Pain .679 .036 .644 .047
PROMIS®-29 Profile Pain
Interference Short Form
.562 .038 .597 .044
PROMIS®-57 Profile Pain
Interference Short Form
.570 .038 .608 .045
PROMIS® Pain
Interference Short Form 6b
.612 .037 .661 .044
AUC is probability of correctly discriminating between patients who have improved and those who have not. Any improvement ≥ “a little better”; 
moderate improvement ≥ “moderately better”
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Table 3
Measure-level responsiveness to SCOPE trial intervention
Pain scale Intervention
change*
(SD) (n = 120)
Control
change*
(SD) (n = 124)
Standardized
Effect Size
(SES)†
Cohen’s
d Effect
Size**
Cronbach’s
Alpha -
Full Sample
BPI severity 0.74 (1.83) 0.11 (1.46) 0.38 0.37 0.872
BPI interference 1.33 (1.94) 0.61 (1.87) 0.37 0.33 0.880
BPI total 1.04 (1.70) 0.36 (1.45) 0.42 0.38 0.909
PEG 1.18 (2.07) 0.44 (1.89) 0.37 0.35 0.764
SF-36 pain −8.24 (16.13) −4.29 (15.76) −0.25 −0.24 0.717
PROMIS®-29 Profile Pain
Interference Short Form
1.81 (5.67) 0.81 (5.88) 0.17 0.14 0.888
PROMIS®-57 Profile Pain
Interference Short Form
2.05 (5.54) 0.67 (5.81) 0.24 0.19 0.946
PROMIS® Pain Interference
Short Form 6b
2.48 (5.27) 0.94 (5.79) 0.28 0.21 0.919
*
change calculated as (baseline - 3 month).
†SES calculated as (intervention group change – control group change) / pooled change score SD.
**Cohen’s d calculated as (intervention group change – control group change) / pooled baseline SD.
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Table 4
BPI, PROMIS® and SF-36 pain interference Items, ordered by content from identical to 
moderately related to unique with corresponding standardized response mean values for 
the clinically improved group
BPI Interference PROMIS® Pain Interference SF-36 Bodily Pain (reverse-scaled)
What number best
describes how, in the last
week, pain has interfered
with your …
SRM‡ In the past 7 days, how
much did pain interfere
with your …
SRM‡ During the past 4
weeks, how much did
pain interfere with
your
Standardized
Response Mean
(SRM)‡
14. enjoyment of life 0.66 4. enjoyment of life 0.16
10. enjoyment of
recreational activities
0.32
5. the things you
usually do for fun
0.25
8. general activity 0.71 1. day to day activities 0.34
11. normal work
(includes both work
outside the home as well
as housework)
0.76 2. work around the
home
0.26 8. normal work,
including both work
outside the home and
housework
−0.66
7. household chores 0.37
11. tasks away from
home (e.g., getting
groceries, running
errands)
0.40
12. relations with other
people
0.47 3. ability to participate
in social activities
0.28
6. enjoyment of social
activities
0.17
8. family life 0.29
12. How often did pain
keep you from
socializing with
others? (frequency)
0.33
9. mood 0.65
10. walking ability 0.56
13. sleep 0.42
9. your ability to
concentrate
0.33
‡SRM calculated as (baseline – 3 month) / SD change score; change calculated as (baseline - 3 month).
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Table 5
Item-level responsiveness to SCOPE trial intervention
Pain item Intervention
change*
(SD) (n = 120)
Control change*
(SD) (n = 124)
Standardized
Effect Size
(SES)†
BPI Severity
bpi1 worst 1.68 (2.26) 0.46 (1.92) 0.56
bpi2 least 0.18 (2.02) −0.04 (1.96) 0.11
bpi3 average ‡ 0.62 (2.10) 0.06 (1.69) 0.29
bpi4 right now 0.38 (2.42) −0.06 (2.04) 0.20
BPI Interference
bpi8 general activity ‡ 1.40 (2.97) 0.62 (2.78) 0.27
bpi9 mood 1.44 (3.02) 0.70 (2.72) 0.26
bpi10 walking 1.57 (3.09) 0.52 (2.36) 0.37
bpi11 normal work 1.19 (2.93) 0.57 (2.75) 0.22
bpi12 relations with other people 0.88 (3.10) 0.44 (2.59) 0.15
bpi13 sleep 1.42 (2.70) 0.80 (2.86) 0.22
bpi14 enjoyment life ‡ 1.45 (2.79) 0.64 (2.82) 0.29
PROMIS® pain
promp1 day to day activities 0.34 (1.02) 0.17 (1.01) 0.17
promp2 work around home 0.26 (1.16) 0.10 (1.06) 0.14
promp3 participation in social activity 0.20 (1.27) 0.01 (1.22) 0.15
promp4 enjoyment of life 0.15 (1.09) 0.20 (1.11) −0.05
promp5 things you usually do for fun 0.28 (1.14) 0.12 (1.24) 0.13
promp6 enjoyment of social activities 0.24 (1.31) −0.01 (1.11) 0.21
promp7 household chores 0.34 (1.13) 0.06 (0.91) 0.27
promp8 family life 0.23 (1.08) 0.11 (1.02) 0.11
promp9 ability to concentrate 0.28 (1.09) 0.20 (1.22) 0.07
promp10 enjoyment recreational activity 0.40 (1.23) 0.06 (1.28) 0.27
promp11 tasks away from home 0.33 (1.15) 0.17 (1.19) 0.13
promp12 socializing with others 0.13 (1.07) −0.02 (1.14) 0.14
SF pain
sf8 pain interfere with normal work −0.36 (0.94) −0.19 (1.03) −0.17
sf9 how much bodily pain −0.48 (0.95) −0.24 (0.86) −0.25
*
change calculated as (baseline - 3 month).
†SES calculated as (intervention group change – control group change) / pooled SD.
‡
Items included in the PEG scale.
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